Chimeric Antigen Receptor (CAR) T-cells

CAR T-cells involves patients’ own immune cells being genetically modified outside the body so they can recognise the leukaemia cells. They are then infused back into the patient to attack the leukaemia cells.

In CLL patients, anti-CD19 CAR-T therapy is particularly effective when it is combined with ibrutinib. However, anti-CD19 CAR-T is not yet approved in UK for CLL, and therefore only available via clinical trials.